Absci Initiates IND-Enabling Studies for ABS-101, Aiming for Enhanced Anti-TL1A Antibody Therapy
Absci has embarked on IND-enabling studies for ABS-101, an anti-TL1A antibody, leveraging its generative AI technology to streamline the development … Read More